- Home
- FTFT vs GNPX Comparison
FTFT vs GNPX Comparison
Compare FTFT & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTFT
- GNPX
- Stock Information
- Founded
- FTFT N/A
- GNPX 2009
- Country
- FTFT United States
- GNPX United States
- Employees
- FTFT N/A
- GNPX N/A
- Industry
- FTFT Business Services
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- FTFT Consumer Discretionary
- GNPX Health Care
- Exchange
- FTFT Nasdaq
- GNPX Nasdaq
- Market Cap
- FTFT 5.9M
- GNPX 6.6M
- IPO Year
- FTFT N/A
- GNPX 2018
- Fundamental
- Price
- FTFT $1.15
- GNPX $0.22
- Analyst Decision
- FTFT
- GNPX
- Analyst Count
- FTFT 0
- GNPX 0
- Target Price
- FTFT N/A
- GNPX N/A
- AVG Volume (30 Days)
- FTFT 46.1K
- GNPX 3.4M
- Earning Date
- FTFT 08-18-2025
- GNPX 08-08-2025
- Dividend Yield
- FTFT N/A
- GNPX N/A
- EPS Growth
- FTFT N/A
- GNPX N/A
- EPS
- FTFT N/A
- GNPX N/A
- Revenue
- FTFT $2,031,913.00
- GNPX N/A
- Revenue This Year
- FTFT N/A
- GNPX N/A
- Revenue Next Year
- FTFT N/A
- GNPX N/A
- P/E Ratio
- FTFT N/A
- GNPX N/A
- Revenue Growth
- FTFT N/A
- GNPX N/A
- 52 Week Low
- FTFT $1.01
- GNPX $0.20
- 52 Week High
- FTFT $5.70
- GNPX $3.97
- Technical
- Relative Strength Index (RSI)
- FTFT 39.32
- GNPX 40.22
- Support Level
- FTFT $1.01
- GNPX $0.22
- Resistance Level
- FTFT $1.16
- GNPX $0.32
- Average True Range (ATR)
- FTFT 0.09
- GNPX 0.03
- MACD
- FTFT 0.01
- GNPX -0.01
- Stochastic Oscillator
- FTFT 25.00
- GNPX 22.07
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.